mavacamten

BMS Presents Robust Mavacamten Results in HCM Ahead of FDA Decision
BMS Presents Robust Mavacamten Results in HCM Ahead of FDA Decision
BioSpace
Bristol Myers Squibb
FDA
clinical trials
mavacamten
obstructive hypertrophic cardiomyopathy
Flag link:
ACC 2022 – Bristol's rare hit could justify Myokardia
ACC 2022 – Bristol's rare hit could justify Myokardia
EP Vantage
ACC
Bristol Myers Squibb
MyoKardia
hypertrophic cardiomyopathy
mavacamten
Flag link:
BMS builds case for mavacamten label ahead of FDA decision
BMS builds case for mavacamten label ahead of FDA decision
Pharmaforum
Bristol Myers Squibb
mavacamten
obtructive hypertrophic cardiomyopathy
MyoKardia
FDA
Flag link:
The biggest launches of 2022: a reboot
The biggest launches of 2022: a reboot
EP Vantage
drug launches
Eli Lilly
tirzepatide
Alnylam
vutrisiran
Roche
Vabysmo
JNJ
Carvykti
Mirati Therapeutics
adagrasib
Bristol Myers Squibb
mavacamten
deucravacitinib
Flag link:
FDA delays its decision on Bristol Myers' $13B heart drug another three months
FDA delays its decision on Bristol Myers' $13B heart drug another three months
Endpoints
Bristol Myers Squibb
mavacamten
ICER
FDA
Flag link:
FDA delays its decision on Bristol Myers' $13B heart drug another three months
FDA delays its decision on Bristol Myers' $13B heart drug another three months
Endpoints
Bristol Myers Squibb
FDA
ICER
mavacamten
obstructive hypertrophic cardiomyopathy
Flag link:
A couple months ahead of its PDUFA data, Bristol Myers rolls out long-term data for mavacamten
A couple months ahead of its PDUFA data, Bristol Myers rolls out long-term data for mavacamten
Endpoints
Bristol Myers Squibb
FDA
mavacamten
MyoKardia
Flag link:
Bristol Myers backs up its case for heart drug mavacamten as FDA weighs app in cardiomyopathy
Bristol Myers backs up its case for heart drug mavacamten as FDA weighs app in cardiomyopathy
Endpoints
Bristol Myers Squibb
mavacamten
FDA
cardiac myopathy
Flag link:
MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021
MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021
Xconomy
MyoKardia
clinical trials
mavacamten
obstructive hypertrophic cardiomyopathy
Flag link:
Myokardia at inflection point as heart drug readout nears
Myokardia at inflection point as heart drug readout nears
BioPharma Dive
MyoKardia
clinical trials
heart disease
mavacamten
Flag link:
Safety qualms in MyoKardia mid-stage study cause investors to pause
Safety qualms in MyoKardia mid-stage study cause investors to pause
Endpoints
MyoKardia
obstructive hypertrophic cardiomyopathy
clinical trials
mavacamten
Flag link:
MyoKardia cuts all ties to Sanofi
MyoKardia cuts all ties to Sanofi
Biopharma Dive
MyoKardia
MYK-224
Sanofi
obstructive hypertrophic cardiomyopathy
mavacamten
Flag link:
MyoKardia raises $251.2M in follow-on
MyoKardia raises $251.2M in follow-on
BioCentury
MyoKardia
mavacamten
Flag link:
Sanofi walks away from MyoKardia heart drug partnership, long before key data readout
Sanofi walks away from MyoKardia heart drug partnership, long before key data readout
Endpoints
Sanofi
MyoKardia
mavacamten
obstructive hypertrophic cardiomyopathy
Flag link:
MyoKardia Heart Drug Boosts Blood Flow, Sends Shares Soaring
MyoKardia Heart Drug Boosts Blood Flow, Sends Shares Soaring
Xconomy
MyoKardia
hypertrophic cardiomyopathy
mavacamten
Flag link: